Chemotherapy and Drug Information

Second-line Weekly Nab-paclitaxel Noninferior to Paclitaxel for Gastric Cancer

Second-line Weekly Nab-paclitaxel Noninferior to Paclitaxel for Gastric Cancer

In a phase 3 trial, researchers determined if weekly nab-paclitaxel was noninferior to weekly solvent-based paclitaxel with respect to overall survival in patients requiring second-line treatment for advanced gastric cancer.

Adding Bortezomib to Rd Improves PFS, OS in Newly Diagnosed Myeloma

Adding Bortezomib to Rd Improves PFS, OS in Newly Diagnosed Myeloma

Researchers investigated whether VRd, which has demonstrated significant efficacy in newly diagnosed multiple myeloma, would improve outcomes in patients with previously untreated myeloma who are not planned for immediate ASCT.

Serum IL-12 May Predict for Chemotherapy-Related Fatigue in Early-Stage Breast Cancer

Serum IL-12 May Predict for Chemotherapy-Related Fatigue in Early-Stage Breast Cancer

In this study, researchers sought to identify physical, neurocognitive, and serologic markers that may correlate with self-reported fatigue before and after (neo)adjuvant chemotherapy for patients with early-stage breast cancer.

Delayed Adjuvant Chemotherapy Not Associated With Survival in NSCLC

Delayed Adjuvant Chemotherapy Not Associated With Survival in NSCLC

Study evaluated differences in survival with respect to the time interval between tumor resection and initiation of postoperative chemotherapy in patients with NSCLC.

What You Do Not Know Could Hurt You: What Women Wish Their Doctors Had Told Them About Chemotherapy Side Effects on Memory and Response to Alcohol

What You Do Not Know Could Hurt You: What Women Wish Their Doctors Had Told Them About Chemotherapy Side Effects on Memory and Response to Alcohol

[Breast Cancer: Basic and Clinical Research] This research examines the incidence of alcohol and memory-related side effects of chemotherapy in female cancer patients.

Patients With Breast Cancer Report More Cognitive Difficulties After Chemotherapy

Patients With Breast Cancer Report More Cognitive Difficulties After Chemotherapy

Researchers sought to evaluate the incidence of cancer-related cognitive impairment in patients with breast cancer in a large prospective, longitudinal, nationwide study. These findings address limitations in previous research.

Escalating Drug Prices Central to Value Discussion of Cancer Treatment Regimens

Escalating Drug Prices Central to Value Discussion of Cancer Treatment Regimens

In his plenary lecture at 2016 SABCS, Peter P. Bach, MD, MAPP, reviewed the factors contributing to escalating drug prices and the significance of drug prices in the value of a cancer treatment regimen.

Drug-Drug Interaction Between Capecitabine and PPIs Reduces Survival in GI Cancers

Drug-Drug Interaction Between Capecitabine and PPIs Reduces Survival in GI Cancers

Drug-drug interaction between capecitabine and common heartburn medications has a negative effect on progression-free survival and overall survival in patients with GI cancer.

Subtype of Glioblastoma Multiforme Responds to Antiangiogenic Chemotherapy

Although previous clinical trials have demonstrated that antiangiogenetic chemotherapy is not effective in GBM, researchers conducted a retrospective of review of perfusion MR images to determine if a phenotypic subtype of GBM may respond to antiangiogenic chemotherapy.

Biomarker Predicts Anthracycline-caused Heart Damage in Women with Breast Cancer

Biomarker Predicts Anthracycline-caused Heart Damage in Women with Breast Cancer

Investigators have identified a genetic biomarker that can help determine congestive heart failure risk in individuals undergoing chemotherapy for breast cancer.

Stat Consult Slideshows

Fluorouracil (5-FU)

This slideshow reviews fluorouracil (5-FU), indicated for palliative treatment of breast cancer, colorectal cancer, gastric cancer, and carcinoma of the pancreas; also adjuvant treatment of colorectal cancer.

Netupitant/Palonosetron (Akynzeo)

This slideshow reviews netupitant/palonosetron (Akynzeo), indicated for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy.

Bevacizumab (Avastin) - cervical cancer

This slideshow reviews bevacizumab (Avastin), indicated for cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan in persistent, recurrent, or metastatic disease.

To view all content in our Stat Consult section, please click here.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs